Dedicated to creating life-changing medicines for people with
limited or no options.
limited or no options.
Research and Development
At Jazz, we use patient-centric innovation to drive our research and development (R&D) strategy, investment and growth. This starts with identifying unmet needs across our therapeutic areas of focus—neuroscience and oncology—and take the best discovery and development approach to solutions, whether that leverages our proprietary, industry-defining research platforms or our collaborations with leading investigators and bioscience companies.
We believe all people, including those who live with complex conditions, deserve new and better therapeutic options. Our teams use their expertise to lead clinical programs across sleep, epilepsy, movement disorders, psychiatry and neurodegenerative diseases, as well as blood and solid tumor cancers. We are committed to innovation, leveraging both our market-defining cannabinoid science capabilities and other proprietary platforms. As part of our commitment to patients with unmet needs, we continually work to expand the science behind our therapies, acquire rights to develop new medicines, and partner with researchers, academia and other industry leaders to advance molecules with great potential to create new or better standards of care.
Pipeline
PRE-CLINICAL
Undisclosed targets
Neuroscience
CombiPlex
Exploratory activities
JZP341
(Long-acting Erwinia asparaginase)
(Long-acting Erwinia asparaginase)
ALL/LBL
Pan-RAF Inhibitor program
Raf & Ras mutant tumors
Undisclosed targets
Ras/Raf/MAP kinase pathway1
Exosome targets
NRAS and up to 4 others)1
NRAS and up to 4 others)1
Hematological malignancies/solid tumors
Undisclosed targets
Oncology
Undisclosed targets
Cannabinoids
PHASE 1
JZP3243
Oxybate extended-release formulation
JZP351
Low Intensity Dosing for higher risk MDS2
JZP351 + other approved therapies
- R/R AML or HMA Failure MDS2
- First-line, fit AML (Phase 1b)
- Low Intensity Therapy for first-line, unfit AML (Phase 1b)
Additional Cannabinoids
Neonatal hypoxic-ischemic encephalopathy
Additional Cannabinoids
Neuropsychiatry targets
PHASE 2
JZP385
Essential tremor
JZP1503
PTSD
Lurbinectedin3
Basket trial: advanced urothelial cancer, large cell neuroendocrine tumor of the lung, HRD+ cancers
JZP351
- HR-MDS (EMSCO)4
- Newly diagnosed older adults with HR-AML4
JZP351 + venetoclax
de novo or R/R AML2
Additional Cannabinoids
Schizophrenia
Additional Cannabinoids
Autism spectrum disorders
PHASE 3
Lurbinectedin1
1L treatment SCLC in combination with atezolizumab
JZP351
- AML or HR-MDS >60 yrs (AML18)4
- Newly diagnosed adults with standard- and HR-AML (AMLSG)4
- Newly diagnosed <22 yrs with AML (COG)4
Cannabidiol3
EMAS
Nabiximols
MS spasticity
Nabiximols3
Spinal cord injury spasticity
REGULATORY
JZP4585
(recombinant Erwinia asparaginase)
ALL/LBL
ALL/LBL
Neuroscience
Hematology/Oncology
Cannabinoids
1Partnered collaboration.
2Jazz & MD Anderson Cancer Center collaboration study.
3Planned.
4Cooperative group study.
5FDA approval on June 30, 2021; plan to submit additional data to support U.S. label update.
Through Jazz’s patented CombiPlex® platform, Jazz is evaluating oncology combinations to support identification of clinical product candidate(s) and is leading a collaborative approach with partners to research and develop new therapies.